We currently don't have sufficient analyst coverage to forecast growth and revenue for Central Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
15.0%
Revenue growth rate
n/a
Future return on equity
n/a
Analyst coverage
None
Last updated
n/a
Recent future growth updates
No updates
Recent updates
In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Central Pharmaceuticals has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
DSE:CENTRALPHL - Analysts future estimates and past financials data (BDT Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2025
34
-19
0
0
N/A
9/30/2025
34
-29
0
0
N/A
6/30/2025
33
-22
-1
-1
N/A
12/31/2024
-28
-44
2
2
N/A
9/30/2024
7
-38
2
2
N/A
6/30/2024
30
-42
3
3
N/A
3/31/2024
112
-59
0
0
N/A
12/31/2023
90
-46
0
0
N/A
9/30/2023
54
-41
0
0
N/A
6/30/2023
29
-44
0
0
N/A
9/30/2022
25
-68
-1
-1
N/A
6/30/2022
26
-68
-1
-1
N/A
6/30/2021
148
-8
-5
2
N/A
6/30/2020
140
-1,107
0
0
N/A
3/31/2020
173
-545
-4
2
N/A
12/31/2019
206
17
-7
4
N/A
9/30/2019
234
30
N/A
8
N/A
6/30/2019
307
57
N/A
10
N/A
3/31/2019
355
83
N/A
35
N/A
9/30/2018
371
81
N/A
30
N/A
6/30/2018
320
61
N/A
29
N/A
3/31/2018
272
29
N/A
8
N/A
9/30/2017
473
112
N/A
21
N/A
6/30/2017
456
109
N/A
20
N/A
3/31/2017
485
133
N/A
7
N/A
12/31/2016
440
116
N/A
2
N/A
9/30/2016
348
81
N/A
-2
N/A
6/30/2016
417
98
N/A
-1
N/A
3/31/2016
477
100
N/A
69
N/A
12/31/2015
553
122
N/A
83
N/A
9/30/2015
624
135
N/A
145
N/A
6/30/2015
661
143
N/A
141
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CENTRALPHL's forecast earnings growth is above the savings rate (4.2%).
Earnings vs Market: Insufficient data to determine if CENTRALPHL's earnings are forecast to grow faster than the BD market
High Growth Earnings: Insufficient data to determine if CENTRALPHL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CENTRALPHL's revenue is forecast to grow faster than the BD market.
High Growth Revenue: Insufficient data to determine if CENTRALPHL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CENTRALPHL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/20 14:17
End of Day Share Price
2026/05/20 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Central Pharmaceuticals Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.